From: Antithrombotic therapy in coronary artery disease patients with atrial fibrillation
 | n (%) | OAC | SAPT | DAPT | DT | TT | P-value |
---|---|---|---|---|---|---|---|
Ischemic stroke | 23 (1.12) | 4 (0.20) | 12 (0.59) | 6 (0.29) | 1 (0.05) | 0 (0) | Â |
 SCAD+AF | 7 (1.25) | 1 (0.18) | 4 (0.72) | 2 (0.36) | 0 (0) | 0 (0) |  |
 ACS + AF | 16 (1.07) | 3 (0.20) | 8 (0.54) | 4 (0.27) | 1 (0.07) | 0 (0) | 0.732 |
Bleeding | 93 (4.54) | 14 (0.68) | 7 (0.34) | 20 (0.05) | 23 (1.12) | 29 (1.41) | Â |
 SCAD+AF | 13 (2.33) | 5 (0.89) | 2 (0.36) | 1 (0.18) | 1 (0.18) | 4 (0.72) |  |
 ACS + AF | 80 (5.37) | 9 (0.60) | 5 (0.34) | 19 (1.27) | 22 (1.48) | 25 (1.68) | 0.003* |
mild bleeding | 59 (2.88) | 11 (0.54) | 6 (0.29) | 12 (0.59) | 16 (0.78) | 14 (0.68) | Â |
 SCAD+AF | 9 (1.61) | 4 (0.72) | 2 (0.36) | 0 (0) | 1 (0.18) | 2 (0.36) |  |
 ACS + AF | 50 (3.35) | 7 (0.47) | 4 (0.27) | 12 (0.80) | 15 (1.01) | 12 (0.80) | 0.035* |
moderate bleeding | 29 (1.41) | 3 (0.15) | 1 (0.05) | 7 (0.34) | 6 (0.29) | 12 (0.59) | Â |
 SCAD+AF | 3 (0.54) | 1 (0.18) | 0 (0) | 1 (0.18) | 0 (0) | 1 (0.18) |  |
 ACS + AF | 26 (1.74) | 2 (0.13) | 1 (0.07) | 6 (0.40) | 6 (0.40) | 11 (0.74) | 0.039* |
major bleeding | 5 (0.24) | 0 (0) | 0 (0) | 1 (0.05) | 1 (0.05) | 3 (0.15) | Â |
 SCAD+AF | 1 (0.18) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (0.18) |  |
 ACS + AF | 4 (0.27) | 0 (0) | 0 (0) | 1 (0.07) | 1 (0.07) | 2 (0.13) | 1.000 |
MI | 19 (0.93) | 7 (0.34) | 5 (0.24) | 2 (0.10) | 3 (0.15) | 2 (0.10) | Â |
 SCAD+AF | 4 (0.72) | 2 (0.36) | 2 (0.36) | 0 (0) | 0 (0) | 0 (0) |  |
 ACS + AF | 15 (1.01) | 5 (0.34) | 3 (0.20) | 2 (0.13) | 3 (0.20) | 2 (0.13) | 0.725 |
All-cause death | 39 (1.90) | 11 (0.54) | 8 (0.39) | 7 (0.34) | 4 (0.20) | 9 (0.44) | Â |
 SCAD+AF | 5 (0.89) | 1 (0.18) | 2 (0.36) | 0 (0.00) | 1 (0.18) | 1 (0.18) |  |
 ACS + AF | 34 (2.28) | 10 (0.67) | 6 (0.40) | 7 (0.47) | 3 (0.20) | 8 (0.54) | 0.041* |